DOCSLIB.ORG

206494Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
206494Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206494Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) CLINICAL PHARMACOLOGY REVIEW NDA: 206-494 Submission Date(s): 06/25/2014 Drug Ceftazidime-Avibactam Trade Name AVICAZ® Injection OCP Reviewers Seong H, Jang, Ph.D. OCP Team Leader Kimberly Bergman, Pharm.D. OCP PM Team Reader Jeffry Florian, Ph.D. OCP Division DCP4 OND Division DAIP Sponsor Cerexa, Inc Relevant IND(s) IND 101,307 Submission Type; Code Original; 1S; Priority Review Formulation; Strength(s) Powder for IV Injection (2 g ceftazidime and 0.5 g avibactam) in a single-use, clear glass vial Indication Treatment of infections proven or suspected to be caused by AVICAZ- susceptible organisms (including ceftazidime resistant, β-lactamase-producing, Gram-negative bacteria) in the following indications: Complicated Intra-abdominal Infection Complicated Urinary Tract Infection, including Acute Pyelonephritis Limited Use Indication: Aerobic Gram-negative Infections with Limited Treatment Options in patients ≥ 18 years of age Dosage and 2.5 g (2 g ceftazidime and 0.5 g avibactam) administered every 8 hours by Administration intravenous (IV) infusion over 2 hours Table of Contents 1. Executive Summary ........................................................................................................... 2 1.1. Recommendation ............................................................................................................ 3 1.2. Phase 4 Commitments .................................................................................................. 3 1.3. Summary of Important Clinical Pharmacology findings ........................................... 3 2. Question-Based Review ........................................................................................................ 8 2.1. General attributes of the drug ..................................................................................... 8 2.2. General Clinical Pharmacology ................................................................................ 11 2.3. Intrinsic Factors .......................................................................................................... 39 2.4. Extrinsic factors........................................................................................................... 50 2.6. Analytical Section ........................................................................................................ 53 3. Labeling Recommendation ............... 58 4. Appendix .............................................................................................................................. 92 4.1. Pharmcometrics Review .................................................................................................. 92 1 Reference ID: 3689069 1. Executive Summary The sponsor submitted this NDA for the use of ceftazidime in combination with avibactam (CAZ-AVI) in the treatment of complicated urinary tract infection (cUTI) and complicated intra- abdominal infection (cIAI). The recommended dosage of CAZ-AVI is 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered every 8 hours (q8h) by intravenous (IV) infusion over 2 hours in patients ≥ 18 years of age with normal renal function or mild renal impairment (creatinine clearance [CRCL] > 50 mL/min). Dose adjustments for patients with moderate and severe renal impairment and patients with end-stage renal disease requiring hemodialysis are recommended (see below). Ceftazidime, the bactericidal β-lactam component of CAZ-AVI, is approved for the treatment of bacterial infections caused by susceptible pathogens. Included among these are cUTI caused by Pseudomonas aeruginosa, Enterobacter spp., Proteus spp., Klebsiella spp., and Escherichia coli and serious intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp., Staphylococcus aureus (methicillin-susceptible strains), and polymicrobial infections caused by aerobic and anaerobic organisms. Resistance to cephalosporins due to β-lactamase-producing bacteria is increasing in various regions worldwide. Avibactam, a β-lactamase inhibitor, is intended to extend the activity of ceftazidime to include Gram-negative bacteria that are non- susceptible to ceftazidime alone due to the production of a β-lactamase. As a β-lactamase inhibitor, avibactam has a spectrum of activity against Ambler class A extended-spectrum β-lactamases (ESBLs), Klebsiella pneumoniae carbapenemase class A (KPC) enzymes, Ambler class C enzymes, and some class D β-lactamases. Avibactam has no meaningful antibacterial activity at achievable concentrations in humans. Avibactam is not approved in any markets worldwide. Clinical studies have been conducted with avibactam in combination with ceftazidime, ceftaroline fosamil, and aztreonam. The clinical development program for CAZ-AVI includes 10 completed Phase 1 clinical pharmacology studies, 1 completed Phase 2 study in patients with cUTI, and 1 completed Phase 2 study in patients with cIAI. In addition, avibactam pharmacokinetic (PK) data from 4 completed Phase 1 clinical pharmacology studies in the ceftaroline fosamil-avibactam (CXL) development program are included in this submission. The proposed dosing regimens provides ~100% of the probability of the PK/PD targets (i.e., 50%fT > MIC for ceftazidime and 50%fT > 1.0 mg/L) at up to 8 µg/mL of CAZ-AVI MIC (i.e., measured using a fixed concentration of avibactam of 4 mg/L). Together with the efficacy results of Phase 2 studies, the proposed dosing regimen of CAZ-AVI appears to be appropriate for organisms with MIC values up to 8 µg/mL of CAZ-AVI MIC. However, the originally proposed dosing regimens for patients with moderate or severe renal impairment are recommended to be revised because (a) the ongoing Phase 3 cIAI study showed a lower clinical cure rate in patients with moderate (CrCL 31-50 mL/min) renal impairment who received the originally proposed dosing regimen and (b) the originally proposed dosing regimens are predicted to result in substantially lower exposure of ceftazidime and avibactam in moderate and severe renal impairment patients compared with patients with normal renal function. 2 Reference ID: 3689069 1.1. Recommendation From a Clinical Pharmacology perspective, we support the approval of AVICAZ injection for the proposed indications in patients ≥ 18 years of age. However, we recommend the originally proposed dosing regimens for patients with moderate and severe renal impairments be revised as follows. Estimated Creatinine Recommended Dosage Regimen for AVICAZ Clearance (mL/min)a > 30 to ≤ 50 1.25 g (1.0 g ceftazidime + 0.25 g avibactam) IV (over 2 hours) every 8 hours > 15 to ≤ 30 0.94 g (0.75 g ceftazidime + 0.188 g avibactam) IV (over 2 hours) every 12 hours > 5 to ≤ 15b 0.94 g (0.75 g ceftazidime + 0.188 g avibactam) IV (over 2 hours) every 24 hours ≤ 5b 0.94 g (0.75 g ceftazidime + 0.188 g avibactam) IV (over 2 hours) every 48 hours a As calculated using the Cockcroft-Gault formula. b Both ceftazidime and avibactam are hemodialyzable; thus, AVICAZ should be administered after hemodialysis on hemodialysis days. 1.2. Phase 4 Commitments Conduct a study to evaluate the efficacy and safety of the alternatively recommended dosages of AVYCAZ in patients with complicated intra-abdominal infection with CRCL ≤50 mL/min. 1.3. Summary of Important Clinical Pharmacology findings Summary of Pharmacokinetics The PK of ceftazidime and avibactam are linear, with Cmax and AUC increasing in proportion to dose. Both avibactam and ceftazidime undergo limited metabolism and there is no evidence of a drug-drug interaction (DDI) between ceftazidime and avibactam. No appreciable accumulation of ceftazidime or avibactam was observed after multiple dose administration of CAZ-AVI for 11 days. Both ceftazidime and avibactam are eliminated primarily by the kidney, with the majority of the dose (80-90% ceftazidime and 85% avibactam) recovered as unchanged drug in urine. The terminal elimination half-life (T½) of ceftazidime and of avibactam is approximately 2 h in patients with normal renal function and substantially prolonged in patients with renal impairment, necessitating reduction of dose and prolongation of the dosing interval in patients with creatinine clearance (CrCL) less than 50 mL/min. A Phase 1 study conducted with CAZ- AVI in healthy adult subjects demonstrated that ceftazidime and avibactam are able to penetrate into bronchial epithelial lining fluid (ELF) to a similar extent and with similar kinetics. The exposure of both drugs in the lung was approximately 30-35% of the exposure in plasma. Less than 10% of ceftazidime is protein bound. The degree of protein binding is independent of concentration. The binding of avibactam to human plasma proteins is also low (5.7% to 8.2%) and similar across the range of concentrations tested in vitro (0.5 to 50 mg/L). The potential for DDIs with CAZ-AVI is low based on the following: both ceftazidime and avibactam undergo limited metabolism; avibactam showed no significant inhibition or induction of cytochrome P450 (CYP) enzymes in vitro, and ceftazidime also showed no CYP induction potential; both avibactam and ceftazidime have low binding to human plasma proteins; and, 3 Reference ID: 3689069 avibactam and ceftazidime did not inhibit any major renal or hepatic transporters in vitro in the clinically relevant exposure range. Avibactam was shown to be a substrate of human organic anion transporter (OAT)1 and OAT3 in vitro, which may contribute to its
Load more

Recommended publications
  • Activity of Aztreonam in Combination with Ceftazidime-Avibactam Against
    Diagnostic Microbiology and Infectious Disease 99 (2021) 115227 Contents lists available at ScienceDirect Diagnostic Microbiology and Infectious Disease journal homepage: www.elsevier.com/locate/diagmicrobio Activity of aztreonam in combination with ceftazidime–avibactam against serine- and metallo-β-lactamase–producing ☆ ☆☆ ★ Pseudomonas aeruginosa , , Michelle Lee a, Taylor Abbey a, Mark Biagi b, Eric Wenzler a,⁎ a College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA b College of Pharmacy, University of Illinois at Chicago, Rockford, IL, USA article info abstract Article history: Existing data support the combination of aztreonam and ceftazidime–avibactam against serine-β-lactamase Received 29 June 2020 (SBL)– and metallo-β-lactamase (MBL)–producing Enterobacterales, although there is a paucity of data against Received in revised form 15 September 2020 SBL- and MBL-producing Pseudomonas aeruginosa. In this study, 5 SBL- and MBL-producing P. aeruginosa (1 Accepted 19 September 2020 IMP, 4 VIM) were evaluated against aztreonam and ceftazidime–avibactam alone and in combination via broth Available online xxxx microdilution and time-kill analyses. All 5 isolates were nonsusceptible to aztreonam, aztreonam–avibactam, – – Keywords: and ceftazidime avibactam. Combining aztreonam with ceftazidime avibactam at subinhibitory concentrations Metallo-β-lactamase produced synergy and restored bactericidal activity in 4/5 (80%) isolates tested. These results suggest that the VIM combination of aztreonam and ceftazidime–avibactam may be a viable treatment option against SBL- and IMP MBL-producing P. aeruginosa. Aztreonam © 2020 Elsevier Inc. All rights reserved. Ceftazidime–avibactam Synergy 1. Introduction of SBLs and MBLs harbored by P. aeruginosa are fundamentally different than those in Enterobacterales (Alm et al., 2015; Kazmierczak et al., The rapid global dissemination of Ambler class B metallo-β- 2016; Periasamy et al., 2020; Poirel et al., 2000; Watanabe et al., lactamase (MBL) enzymes along with their increasing diversity across 1991).
    [Show full text]
  • FDA Drug Safety Communication: FDA Cautions About Dose Confusion and Medication Error with Antibacterial Drug Avycaz (Ceftazidime and Avibactam)
    FDA Drug Safety Communication: FDA cautions about dose confusion and medication error with antibacterial drug Avycaz (ceftazidime and avibactam) Safety Announcement [09-22-2015] The U.S. Food and Drug Administration (FDA) is warning health care professionals about the risk for dosing errors with the intravenous antibacterial drug Avycaz (ceftazidime and avibactam) due to confusion about the drug strength displayed on the vial and carton labels. Avycaz was initially approved with the vial and carton labels displaying the individual strengths of the two active ingredients (i.e., 2 gram/0.5 gram); however, the product is dosed based on the sum of the active ingredients (i.e., 2.5 gram). To prevent medication errors, we have revised the labels to indicate that each vial contains Avycaz 2.5 gram, equivalent to ceftazidime 2 gram and avibactam 0.5 gram (see Photos). Avycaz is approved for intravenous administration to treat complicated infections in the urinary tract, or in combination with the antibacterial drug metronidazole to treat complicated infections in the abdomen in patients with limited or no alternative treatment options. Antibacterial drugs work by killing or stopping the growth of bacteria that can cause illness. Since Avycaz’s approval in February 2015, we have received reports of three medication error cases related to confusion on how the strength was displayed on the Avycaz vial and carton labels. Two cases stated that the errors occurred during preparation of the dose in the pharmacy. The third case described concern about the potential for confusion because the strength displayed for Avycaz differs from how the strength is displayed for other beta-lactam/beta-lactamase antibacterial drugs.
    [Show full text]
  • Idweek16 CAZ-AVI PSA 1831.Pdf
    Helio S. Sader, MD, PhD IDWEEK 2016 Antimicrobial Activity of Ceftazidime-Avibactam Tested Against Pseudomonas aeruginosa Isolates from JMI Laboratories 1831 North Liberty, IA, USA USA Hospitals Stratified by Site of Infection: Results from the INFORM Surveillance Program, 2013-2015 www.jmilabs.com HS SADER, M CASTANHEIRA, MD HUBAND, RK FLAMM ph. 319.665.3370 fax 319.665.3371 JMI Laboratories, North Liberty, Iowa, USA [email protected] Ceftazidime-avibactam is a combination agent consisting of the non-β- Table 1. Activity of ceftazidime-avibactam and comparator antimicrobial Figure 2. Antimicrobial activity of ceftazidime-avibactam, ceftazidime, Abstract lactam β-lactamase inhibitor avibactam and the broad-spectrum Results agents when tested against Pseudomonas aeruginosa from USA meropenem, and piperacillin-tazobactam when tested against P. aeruginosa cephalosporin, ceftazidime. Avibactam is a member of the hospitals (2013-2015). and stratified by site of infection. Background: Ceftazidime (CAZ)-avibactam (AVI) was approved by the United • Isolates were mostly from pneumonia (n=2,903; 52.9%), skin and skin diazabicyclooctanes (DBOs), a novel class of non-β-lactam β-lactamase MIC MIC CLSIa States Food and Drug Administration (US-FDA) for treatment of complicated intra- structure (SSSI; 1,286; 23.4%), bloodstream (BSI; 436; 7.9%), urinary Antimicrobial Agent 50 90 abdominal and urinary tract infections in 2015 and is under clinical development inhibitors which has a different mechanism of action when compared with (μg/mL) %S %I %R 100 tract (UTI; 417; 7.6%) and intra-abdominal infections (IAI; 199; 3.6%). All isolates (5,486) 90 for treatment of hospital-acquired pneumonia.
    [Show full text]
  • Antimicrobial Activity of Ceftaroline Combined with Avibactam Tested Against Contemporary (2012) Helio S
    Antimicrobial Activity of Ceftaroline Combined with Avibactam Tested Against Contemporary (2012) Helio S. Sader, MD, PhD JMI Laboratories Bacteria Collected from USA Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) North Liberty, IA, USA ECCMID 2013 www.jmilabs.com HS SADER, RK FLAMM, RN JONES ph. 319.665.3370 P1620 fax 319.665.3371 JMI Laboratories, North Liberty, Iowa, USA [email protected] Table 2. Antimicrobial activities of ceftaroline-avibactam, ceftaroline and comparator agents when tested against gram-negative organisms from Abstract Introduction Results skin and skin structure infections (USA, 2012). Conclusions Objective: To evaluate the activity of ceftaroline Ceftaroline, the active metabolite of the prodrug ceftaroline • The most common organisms were S. aureus (3,481; Organism (no tested)/ MIC (mg/L) %S / %I / %R • Ceftaroline-avibactam was highly active antimicrobial agent 50% 90% Range CLSIa EUCASTa (CPT)-avibactam (AVI) tested against bacteria from fosamil, is a cephalosporin with notable in vitro bactericidal 50.5% MRSA), E. coli (444; 13.3% ESBL-phenotype), β- E. coli (444) against ESBL-phenotype and carbapenem- ABSSSI collected in USA hospitals in 2012. CPT activity against organisms commonly responsible for haemolytic streptococci (βHS; 389) and Klebsiella spp. Ceftaroline-avibactam 0.03 0.06 ≤0.015 – 0.5 - / - / - - / - / - non-susceptible Enterobacteriaceae Ceftaroline 0.12 32 ≤0.015 – >32 83.3 / 2.7 / 14.0 83.3 / 0.0 / 16.7 fosamil is a novel parenteral cephalosporin community-acquired
    [Show full text]
  • Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review
    Infection and Drug Resistance Dovepress open access to scientific and medical research Open Access Full Text Article CASE SERIES Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review Qian Zhou1 Background: Central nervous system (CNS) infections caused by multidrug-resistant Hao Wang2 (MDR) and extensively drug-resistant (XDR) Gram-negative bacillus, including carbape­ Tianxiang Zhan2 nem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa, are associated with Xiaofeng Yang1,2 high mortality rates. Clinical trials of ceftazidime/avibactam (CAZ/AVI) on infections of Liang Wen2 other systems indicate that they are effective against these infections. However, clinical studies on the efficacies of CAZ/AVI in the treatment of CNS infections have not been done. 1 Department of Emergency and Trauma Case Presentation: We evaluated 3 patients diagnosed with MDR/XDR Gram-negative Center, The International Medical Center, The First Affiliated Hospital, bacillus-associated CNS infections, and effectively treated with CAZ/AVI. Moreover, we Zhejiang University School of Medicine, performed literature reviews. Before the onset of CNS infections, the 3 patients were Hangzhou, Zhejiang Province, 310003, subjected to neurosurgical operations, treated with mechanical ventilation, long-term inten­ People’s Republic of China; 2Department of Neurosurgery, The First Affiliated sive care unit therapy, and various antibiotics. By intravenously administering CAZ/AVI, Hospital, Zhejiang University School of combined with another antibiotic, the MDR/XDR K. pneumoniae and P. aeruginosa asso­ Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China ciated ventriculitis was effectively treated in the 3 patients. Conclusion: CAZ/AVI is a viable treatment option for CNS infections caused by MDR/ XDR Gram-negative bacteria.
    [Show full text]
  • 辻氏②P1314(900X1900)
    P1314 Surveillance of Cefiderocol In Vitro Activity against Gram-Negative Clinical Isolates Collected Contact Information : Masakatsu Tsuji in Europe: SIDERO-WT-2014 Address: 3-1-1, Futaba-cho, Toyonaka, Osaka, 561-0825, JAPAN TEL: +81-6-6331-8272 27th ECCMID 1) 2) 1) 3) 2) FAX: +81-6-6331-8612 Masakatsu Tsuji , Meredith Hackel , Yoshinori Yamano , Roger Echols and Daniel F Sahm E-mail address: [email protected] Vienna, Austria 22-25 April, 2017 1) Shionogi & Co., Ltd., Osaka JP, 2) IHMA, Inc. Schaumburg, IL, US, 3) ID3C, LLC, Easton CT, US Compound testing cefiderocol, iron-deficient cation-adjusted Muller-Hinton Broth ABSTRACT Cefiderocol, cefepime, ceftazidime-avibactam, ceftolozane-tazobactam, (ID-CAMHB) was used according to CLSI approved guidelines (3, 4). The RESULTS Background: ciprofloxacin, colistin and meropenem were used. cefiderocol MIC was read as the first drug well in which the growth was significantly reduced (i.e. a button of < 1 mm or light/faint turbidity) relative • Cefiderocol MIC50 and MIC90 values were the lowest of all compounds tested (Table 2, Figure 3-5). Figure 4. Cumulative percentage of cefiderocol MIC against 570 carbapenem- The emergence and dissemination of potent resistance mechanisms among Gram-negative bacterial Antimicrobial Susceptibility Testing to the growth observed in the growth control. Escherichia coli ATCC 25922 • The cefiderocol MIC90 value was 1 mg/L for all Enterobacteriaceae and 4 mg/L for resistant A. baumanii from EU. species underscores the need for the development of new and effective therapeutic choices to treat Antimicrobial susceptibility testing was done using broth microdilution meropenem-resistant Enterobacteriaceae.
    [Show full text]
  • CLSI AST News Update Janet A
    Volume 3, Issue 2 Spring 2018 CLSI Subcommittee on Antimicrobial Susceptibility Testing CLSI AST News Update Janet A. Hindler, MCLS MT(ASCP) F(AAM), Editor Audrey N. Schuetz, MD, MPH, D(ABMM), Editor The CLSI Outreach Working Group (ORWG) is providing this Newsletter to highlight some recent issues related to antimicrobial susceptibility testing Inside This Issue: and reporting. We are listing links to some new educational materials and reminding you where you can find information about the CLSI AST Featured Article: Part 1 Subcommittee proceedings. New β-lactam combination agents for the treatment of Gram-negative bacterial infections: what the clinical microbiologist needs to know! ..................................................4 Upcoming Webinar: Featured Article: Part 2 Why all the fuss over quality control of Preparation, Presentation, and Promotion of Cumulative Antibiograms To β-lactam combination agents? ........................8 Support Antimicrobial Stewardship Programs Case Study: Cefazolin, Urine, and October 16, 2018 | 1:00–2:00 PM Eastern (US) Time Escherichia coli, Klebsiella pneumoniae, and Presenters: Proteus mirabilis: Entertaining Solutions Sharon Erdman, PharmD for Antimicrobial Susceptibility Testing and Clinical Professor, Purdue University College of Pharmacy Reporting ..........................................................12 Infectious Diseases Clinical Pharmacist/Co-Director OPAT Program, Eskenazi Health Burning Question: What Should Clinical Laboratorians Know About Gonorrhea in Patricia J. Simner, PhD, D(ABMM) 2018? ................................................................15 Associate Professor of Pathology, Johns Hopkins University Director of Medical Bacteriology and Parasitology Laboratories, Johns Hopkins Hot Topic: It’s Enough to mec You Crazy! ...18 Hospital What does the CLSI AST Subcommittee do? The first edition of the CLSI AST News Update (Vol 1, Issue 1, Spring 2016) described details about the organization and operation of the CLSI AST Subcommittee.
    [Show full text]
  • Global Trends of Antimicrobial Susceptibility of Ceftaroline and Ceftazidime-Avibactam: a Surveillance Study from the ATLAS Program (2012- 2016)
    Global Trends of Antimicrobial Susceptibility of Ceftaroline and Ceftazidime-Avibactam: A Surveillance Study from the ATLAS Program (2012- 2016) Hui Zhang Peking Union Medical College Hospital Yingchun Xu Peking Union Medical College Hospital Peiyao Jia Peking Union Medical College Hospital Ying Zhu Peking Union Medical College Hospital Ge Zhang Peking Union Medical College Hospital Jingjia Zhang Peking Union Medical College Hospital Simeng Duan Peking Union Medical College Hospital Wei Kang Peking Union Medical College Hospital Tong Wang Peking Union Medical College Hospital Ran Jing Peking Union Medical College Hospital Jingwei Cheng Peking Union Medical College Hospital Yali Liu Peking Union Medical College Hospital Qiwen Yang ( [email protected] ) Research Keywords: ceftaroline, ceftazidime-avibactam, antibiotics, surveillance, antimicrobial resistance Page 1/16 Posted Date: June 4th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-31962/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on October 27th, 2020. See the published version at https://doi.org/10.1186/s13756-020-00829-z. Page 2/16 Abstract Background: Antibiotic resistance is a global health threat.This study reported the global trends of antimicrobial susceptibility ofceftaroline and ceftazidime-avibactam using data from the Antimicrobial Testing Leadership And Surveillance (ATLAS)programbetween2012and2016. Methods:Theminimum inhibitory concentrations
    [Show full text]
  • Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria
    Journal of Clinical Medicine Review An Update on Eight “New” Antibiotics against Multidrug-Resistant Gram-Negative Bacteria Erlangga Yusuf * , Hannelore I. Bax, Nelianne J. Verkaik and Mireille van Westreenen Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; [email protected] (H.I.B.); [email protected] (N.J.V.); [email protected] (M.v.W.) * Correspondence: [email protected] Abstract: Infections in the ICU are often caused by Gram-negative bacteria. When these microorgan- isms are resistant to third-generation cephalosporines (due to extended-spectrum (ESBL) or AmpC beta-lactamases) or to carbapenems (for example carbapenem producing Enterobacteriales (CPE)), the treatment options become limited. In the last six years, fortunately, there have been new an- tibiotics approved by the U.S. Food and Drug Administration (FDA) with predominant activities against Gram-negative bacteria. We aimed to review these antibiotics: plazomicin, eravacycline, temocillin, cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam. Temocillin is an antibiotic that was only approved in Belgium and the UK several decades ago. We reviewed the in vitro activities of these new antibiotics, especially against ESBL and CPE microorganisms, potential side effects, and clinical studies in complicated urinary tract infections (cUTI), intra-abdominal infections (cIAI), and hospital-acquired pneumonia/ventilator- associatedpneumonia (HAP/VAP). All of these new antibiotics are active against ESBL, and almost all of them are active against CPE caused by KPC beta-lactamase, but only some of them are active against CPE due to MBL or OXA beta-lactamases.
    [Show full text]
  • Treatment of Carbapenem Resistant Gram Negative Infections
    Treatment of Carbapenem Resistant Gram-Negative Infections STEPHANIE GIANCOLA, PHARMD, BCPS, BCIDP CLINICAL PHARMACIST, INFECTIOUS DISEASES BROOKE ARMY MEDICAL CENTER APRIL 11, 2021 Disclosures & Disclaimer Disclosure: ◦ No potential conflicts of interest in relation to this presentation Disclaimer: ◦ The view(s) expressed herein are those of the presenter and do not reflect the official policy or position of Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force and Department of Defense or the U.S. Government Objectives 1. Describe the prevalence of carbapenem resistant Gram-negative infections 2. Explain the mechanisms of carbapenem resistance in Gram-negative bacteria 3. List the treatment options for carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii infections Antimicrobial Resistance CDC. Antibiotic Resistance Threats in the United States, 2019 Antimicrobial Resistance Threats Urgent threats • Carbapenem-resistant Acinetobacter • Carbapenem-resistant Enterobacterales (CRE) • Candida auris • Clostridioides difficile • Drug-resistant Neisseria gonorrhoeae Serious threats • Drug-resistant Campylobacter • Drug-resistant Candida • ESBL-producing Enterobacteriaceae • VRE • MDR Pseudomonas aeruginosa • Drug-resistant Non-typhoidal Salmonella Typhi • Drug-resistant Shigella • MRSA • Drug-resistant Streptococcus pneumoniae • Drug-resistant TB Concerning threats • Erythromycin-resistant Group
    [Show full text]
  • The in Vitro Activity of Ceftazidime–Avibactam Against 417 Gram
    braz j infect dis 2 0 1 7;2 1(5):569–573 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Letter to the Editor The in vitro activity of ceftazidime–avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil Dear Editor: freundii, Enterobacter aerogenes, E. cloacae, Morganella morgan- nii, Providencia stuartii, and Serratia marcescens likely resulted Avibactam is a new non-␤-lactam ␤-lactamase inhibitor that from the ceftazidime-nonsusceptible isolates of those species 6 restores the in vitro activity of ceftazidime against isolates producing stably derepressed AmpC ␤-lactamases. This is of Enterobacteriaceae and Pseudomonas aeruginosa that harbor consistent with the observation that >90% of the isolates of Ambler molecular class A, class C and some class D ␤- those species remained susceptible to meropenem (Table 1). 1 2 lactamases, but not those harboring metallo-␤-lactamases. Of the 27 unselected isolates of K. pneumoniae tested, only Ceftazidime–avibactam and comparator antibacterial agents 70.4% were susceptible to meropenem, and 37–41% were sus- were tested by reference broth microdilution against 417 ceptible to the other ␤-lactam comparator agents tested, non-repetitive Gram-negative bacilli (387 unselected, plus including the ␤-lactam/␤-lactamase-inhibitor combination 30 selected blaKPC-positive, meropenem–nonsusceptible, Kleb- piperacillin-tazobactam. Susceptibility to levofloxacin was siella pneumoniae) collected prospectively from medical centers also low, at 40.7%, and almost 15% of the isolates lacked at Hospital das Clínicas da Faculdade de Medicina da Uni- susceptibility to colistin. Of the 30 selected meropenem- versidade de São Paulo, Brazil, in 2014 and 2015.
    [Show full text]
  • 206494Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206494Orig1s000 MICROBIOLOGY / VIROLOGY REVIEW(S) Product Quality Microbiology Review 27 January 2015 NDA: 206-494/N-000 Drug Product Name Proprietary: Avycaz™ Non-proprietary: ceftazidime-avibactam for injection Review Number: 1 Dates of Submission(s) Covered by this Review Submit Received Review Request Assigned to Reviewer 25 June 2014 25 June 2014 na 08 July 2014 18 August 2014 18 August 2014 na na Submission History (for 2nd Reviews or higher): NA Applicant/Sponsor Name: Cerexa, Inc. Address: 2100 Franklin St., Suite 900 Oakland, CA 94612 Representative: Kristina Haeckl, RAC Executive Director, Regulatory Affairs, Telephone: 510-285-9482 Name of Reviewer: Robert J. Mello, Ph.D. Conclusion: Recommended for Approval NDA 206494/N000 Microbiology Review #1 Endorsement page: Digitally signed by Robert J. Mello -A Robert J. DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=130 Robert J. Mello, Ph.D. 0369984, cn=Robert J. Mello -A Senior Microbiology Reviewer Mello -A Date: 2015.02.03 07:54:05 -05'00' OPQ/OPF/DMA Digitally signed by Neal J. Sweeney -A Neal J. Sweeney, Ph.D. Neal J. DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Senior Microbiology Reviewer 0.9.2342.19200300.100.1.1=1300 OPQ/OPF/DMA Sweeney -A 109587, cn=Neal J. Sweeney -A Date: 2015.02.03 08:26:50 -05'00' Page 26 of 26 DIVISION OF ANTI-INFECTIVE PRODUCTS CLINICAL MICROBIOLOGY REVIEW NDA: 206494 DATE REVIEW COMPLETED: 11-06-2014 Ceftazidime-avibactam Date Company Submitted: 06/25/14 Date received by CDER: 06/25/14 Date Assigned: 06/25/14 Reviewer: Avery Goodwin, Ph.D.
    [Show full text]